First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
Status:
Completed
Trial end date:
2013-03-18
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability,
pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the
effect of the investigated drug on the body) of NNC0195-0092 (somapacitan) compared to
placebo in healthy male subjects.